NewEdge Advisors’s Krystal Biotech KRYS Stock Holding History

NewEdge Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.8K	Sell	34 -3	-8%	-$896	﹤0.01%	3480
2026 Q1	$9.64K	Sell	37 -35	-49%	-$9.31K	﹤0.01%	3412
2025 Q4	$17.8K	Buy	72 +38	+112%	+$8K	﹤0.01%	3287
2025 Q3	$6.06K	Hold	34	–	–	﹤0.01%	3476
2025 Q2	$4.72K	Hold	34	–	–	﹤0.01%	3427
2025 Q1	$6.19K	Hold	34	–	–	﹤0.01%	3243
2024 Q4	$5.38K	Hold	34	–	–	﹤0.01%	3221
2024 Q3	$6.25K	Hold	34	–	–	﹤0.01%	3085
2024 Q2	$6.3K	Hold	34	–	–	﹤0.01%	3016
2024 Q1	$6.11K	Hold	34	–	–	﹤0.01%	3064
2023 Q4	$4.26K	Hold	34	–	–	﹤0.01%	3163
2023 Q3	$3.98K	Sell	34 -259	-88%	-$31.6K	﹤0.01%	2877
2023 Q2	$34.4K	Hold	293	–	–	﹤0.01%	2220
2023 Q1	$23.5K	Sell	293 -6,094	-95%	-$479K	﹤0.01%	2284
2022 Q4	$506	Buy	6,387 +29	+0.5%	+$2.15K	﹤0.01%	3169
2022 Q3	$443K	Buy	+6,358	New	+$459K	0.01%	1024

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NewEdge Advisors's KRYS Position: Q2 2026 in Review

NewEdge Advisors reduced its Krystal Biotech (KRYS) stake by 8.1% in Q2 2026, selling an estimated $896 and leaving 34 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3480.

NewEdge Advisors first reported a position in KRYS in Q3 2022 and has held it in 16 quarters since. The position peaked at $443K in Q3 2022. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

NewEdge Advisors held 34 shares of Krystal Biotech worth $12.8K as of Q2 2026.
NewEdge Advisors sold 3 Krystal Biotech shares in Q2 2026, an estimated $896.
Krystal Biotech made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3480 holding.
NewEdge Advisors first reported a position in Krystal Biotech in Q3 2022 and has held it in 16 quarters since.
NewEdge Advisors's Krystal Biotech position peaked at $443K in Q3 2022.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.